Adrenocortical carcinoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Ahmed Younes (talk | contribs) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 7: | Line 7: | ||
== Adrenocortical carcinoma secondary prevention == | == Adrenocortical carcinoma secondary prevention == | ||
*Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | *Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. <ref name="urlAmerican Cancer Society Recommendations for Colorectal Cancer Early Detection">{{cite web |url=https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html |title=American Cancer Society Recommendations for Colorectal Cancer Early Detection |format= |work= |accessdate=}}</ref> | ||
*Surveillance intervals may be increased to 6 months for the next 5 years. | *Surveillance intervals may be increased to 6 months for the next 5 years. | ||
*Surveillance should also include: | *Surveillance should also include: | ||
**[[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | **[[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]], | ||
**The use of [[FDG-PET]] for [[lesions]] of an unclear nature | **The use of [[FDG-PET]] for [[lesions]] of an unclear nature, | ||
**Laboratory evaluation for [[steroid hormones]] | **Laboratory evaluation for [[steroid hormones]], | ||
**Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | **Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]]. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 13:17, 31 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma secondary prevention |
|
Risk calculators and risk factors for Adrenocortical carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Patients are followed for periods up to five years after undergoing remission to check for the recurrence of the tumor.
Adrenocortical carcinoma secondary prevention
- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. [1]
- Surveillance intervals may be increased to 6 months for the next 5 years.
- Surveillance should also include: